Blood:TET2缺陷促进异常红系祖细胞克隆扩增,导致无效造血

2018-09-26 MedSci MedSci原创

骨髓增生异常综合征(MDS)是克隆性造血干细胞失调,特点是无效造血。贫血是MDS患者的典型细胞减少症,但MDS异常红系造血的分子机制尚不完全清楚。近期有研究表明DNA双加氧酶TET2杂合功能丧失性突变是MDS最常见的突变之一,TET2缺陷可扰乱红系分化。但是,TET2在红系生成障碍中的作用机制尚未完全明确。Xiaoli Qu等人发现TET2缺陷最初会导致干细胞因子(SCF)依赖性的过度增殖,并损伤

骨髓增生异常综合征(MDS)是克隆性造血干细胞失调,特点是无效造血。贫血是MDS患者的典型细胞减少症,但MDS异常红系造血的分子机制尚不完全清楚。

近期有研究表明DNA双加氧酶TET2杂合功能丧失性突变是MDS最常见的突变之一,TET2缺陷可扰乱红系分化。但是,TET2在红系生成障碍中的作用机制尚未完全明确。

Xiaoli Qu等人发现TET2缺陷最初会导致干细胞因子(SCF)依赖性的过度增殖,并损伤人CFU-E细胞的分化,这可被c-Kit抑制剂逆转。研究人员进一步发现上述情况是由于c-Kit磷酸化增强伴随磷酸酶SHP-1(c-Kit的负性调控因子)表达降低导致的。

在后期,TET2缺陷导致祖细胞积累,积累的祖细胞可表达正常的CFU-E的表明标志物,但功能不同。与仅需要EPO促进增殖的正常CFU-E不同,异常的祖细胞需要SCF和EPO,并表现为分化受损。研究人员把这类祖细胞称为“标记-CFU-E”。此外,研究人员还发现酪氨酸激酶AXL在“标记-CFU-E”中的表达水平增加,AXL水平增高导致AKT和ERK激活增加。而且,“标记-CFU-E”改变的增殖和分化可部分被AXL抑制剂挽救。

本研究表明TET2在红系生成中发挥重要作用,研究人员通过TET2缺陷促进无效造血揭示了既往所不知的机制。


原始出处:

Xiaoli Qu,et al. TET2 deficiency leads to stem cell factor dependent clonal expansion of dysfunctional erythroid progenitors. Blood  2018  :blood-2018-05-853291;  doi: https://doi.org/10.1182/blood-2018-05-853291

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1660175, encodeId=e22816601e527, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Thu Nov 15 05:49:00 CST 2018, time=2018-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967438, encodeId=3541196e438ec, content=<a href='/topic/show?id=922e589686b' target=_blank style='color:#2F92EE;'>#无效造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58968, encryptionId=922e589686b, topicName=无效造血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Jul 07 02:49:00 CST 2019, time=2019-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011392, encodeId=79f92011392b1, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Mon Sep 02 11:49:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446530, encodeId=90f8144653084, content=<a href='/topic/show?id=2c001e30276' target=_blank style='color:#2F92EE;'>#TET2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17302, encryptionId=2c001e30276, topicName=TET2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aeee5221880, createdName=neurowu, createdTime=Fri Sep 28 06:49:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494645, encodeId=735a1494645ca, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Fri Sep 28 06:49:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512453, encodeId=84fa1512453d8, content=<a href='/topic/show?id=f802e4102cb' target=_blank style='color:#2F92EE;'>#祖细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74102, encryptionId=f802e4102cb, topicName=祖细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f18310470858, createdName=12498636m52(暂无昵称), createdTime=Fri Sep 28 06:49:00 CST 2018, time=2018-09-28, status=1, ipAttribution=)]
    2018-11-15 aids221
  2. [GetPortalCommentsPageByObjectIdResponse(id=1660175, encodeId=e22816601e527, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Thu Nov 15 05:49:00 CST 2018, time=2018-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967438, encodeId=3541196e438ec, content=<a href='/topic/show?id=922e589686b' target=_blank style='color:#2F92EE;'>#无效造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58968, encryptionId=922e589686b, topicName=无效造血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Jul 07 02:49:00 CST 2019, time=2019-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011392, encodeId=79f92011392b1, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Mon Sep 02 11:49:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446530, encodeId=90f8144653084, content=<a href='/topic/show?id=2c001e30276' target=_blank style='color:#2F92EE;'>#TET2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17302, encryptionId=2c001e30276, topicName=TET2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aeee5221880, createdName=neurowu, createdTime=Fri Sep 28 06:49:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494645, encodeId=735a1494645ca, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Fri Sep 28 06:49:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512453, encodeId=84fa1512453d8, content=<a href='/topic/show?id=f802e4102cb' target=_blank style='color:#2F92EE;'>#祖细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74102, encryptionId=f802e4102cb, topicName=祖细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f18310470858, createdName=12498636m52(暂无昵称), createdTime=Fri Sep 28 06:49:00 CST 2018, time=2018-09-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1660175, encodeId=e22816601e527, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Thu Nov 15 05:49:00 CST 2018, time=2018-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967438, encodeId=3541196e438ec, content=<a href='/topic/show?id=922e589686b' target=_blank style='color:#2F92EE;'>#无效造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58968, encryptionId=922e589686b, topicName=无效造血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Jul 07 02:49:00 CST 2019, time=2019-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011392, encodeId=79f92011392b1, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Mon Sep 02 11:49:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446530, encodeId=90f8144653084, content=<a href='/topic/show?id=2c001e30276' target=_blank style='color:#2F92EE;'>#TET2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17302, encryptionId=2c001e30276, topicName=TET2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aeee5221880, createdName=neurowu, createdTime=Fri Sep 28 06:49:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494645, encodeId=735a1494645ca, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Fri Sep 28 06:49:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512453, encodeId=84fa1512453d8, content=<a href='/topic/show?id=f802e4102cb' target=_blank style='color:#2F92EE;'>#祖细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74102, encryptionId=f802e4102cb, topicName=祖细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f18310470858, createdName=12498636m52(暂无昵称), createdTime=Fri Sep 28 06:49:00 CST 2018, time=2018-09-28, status=1, ipAttribution=)]
    2019-09-02 yhy100200
  4. [GetPortalCommentsPageByObjectIdResponse(id=1660175, encodeId=e22816601e527, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Thu Nov 15 05:49:00 CST 2018, time=2018-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967438, encodeId=3541196e438ec, content=<a href='/topic/show?id=922e589686b' target=_blank style='color:#2F92EE;'>#无效造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58968, encryptionId=922e589686b, topicName=无效造血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Jul 07 02:49:00 CST 2019, time=2019-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011392, encodeId=79f92011392b1, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Mon Sep 02 11:49:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446530, encodeId=90f8144653084, content=<a href='/topic/show?id=2c001e30276' target=_blank style='color:#2F92EE;'>#TET2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17302, encryptionId=2c001e30276, topicName=TET2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aeee5221880, createdName=neurowu, createdTime=Fri Sep 28 06:49:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494645, encodeId=735a1494645ca, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Fri Sep 28 06:49:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512453, encodeId=84fa1512453d8, content=<a href='/topic/show?id=f802e4102cb' target=_blank style='color:#2F92EE;'>#祖细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74102, encryptionId=f802e4102cb, topicName=祖细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f18310470858, createdName=12498636m52(暂无昵称), createdTime=Fri Sep 28 06:49:00 CST 2018, time=2018-09-28, status=1, ipAttribution=)]
    2018-09-28 neurowu
  5. [GetPortalCommentsPageByObjectIdResponse(id=1660175, encodeId=e22816601e527, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Thu Nov 15 05:49:00 CST 2018, time=2018-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967438, encodeId=3541196e438ec, content=<a href='/topic/show?id=922e589686b' target=_blank style='color:#2F92EE;'>#无效造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58968, encryptionId=922e589686b, topicName=无效造血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Jul 07 02:49:00 CST 2019, time=2019-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011392, encodeId=79f92011392b1, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Mon Sep 02 11:49:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446530, encodeId=90f8144653084, content=<a href='/topic/show?id=2c001e30276' target=_blank style='color:#2F92EE;'>#TET2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17302, encryptionId=2c001e30276, topicName=TET2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aeee5221880, createdName=neurowu, createdTime=Fri Sep 28 06:49:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494645, encodeId=735a1494645ca, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Fri Sep 28 06:49:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512453, encodeId=84fa1512453d8, content=<a href='/topic/show?id=f802e4102cb' target=_blank style='color:#2F92EE;'>#祖细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74102, encryptionId=f802e4102cb, topicName=祖细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f18310470858, createdName=12498636m52(暂无昵称), createdTime=Fri Sep 28 06:49:00 CST 2018, time=2018-09-28, status=1, ipAttribution=)]
    2018-09-28 俅侠
  6. [GetPortalCommentsPageByObjectIdResponse(id=1660175, encodeId=e22816601e527, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Thu Nov 15 05:49:00 CST 2018, time=2018-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967438, encodeId=3541196e438ec, content=<a href='/topic/show?id=922e589686b' target=_blank style='color:#2F92EE;'>#无效造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58968, encryptionId=922e589686b, topicName=无效造血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Jul 07 02:49:00 CST 2019, time=2019-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011392, encodeId=79f92011392b1, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Mon Sep 02 11:49:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446530, encodeId=90f8144653084, content=<a href='/topic/show?id=2c001e30276' target=_blank style='color:#2F92EE;'>#TET2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17302, encryptionId=2c001e30276, topicName=TET2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aeee5221880, createdName=neurowu, createdTime=Fri Sep 28 06:49:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494645, encodeId=735a1494645ca, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Fri Sep 28 06:49:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512453, encodeId=84fa1512453d8, content=<a href='/topic/show?id=f802e4102cb' target=_blank style='color:#2F92EE;'>#祖细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74102, encryptionId=f802e4102cb, topicName=祖细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f18310470858, createdName=12498636m52(暂无昵称), createdTime=Fri Sep 28 06:49:00 CST 2018, time=2018-09-28, status=1, ipAttribution=)]

相关资讯

Nat Genet:TET2如何被招募到染色质?王建龙组从RNA结合蛋白角度给出部分答案

有关TET家族蛋白参与DNA去甲基化的作用及其相关的生物学功能这里不再赘述,相信关注生物学的同行多少都会有些了解。尽管,过去将近十年的时间里,有非常多的关于TET蛋白的研究报道,但是有一些生物学问题很长时间都没有被很好的解决。

Blood:Bcor剂量不足可促进骨髓增生异常综合征的发生发展

中心点:Bcor剂量不足会促进骨髓增生异常综合征的发生发展。在骨髓增生异常综合征的病理过程中,Bcor剂量不足与Tet2缺失相互协作。摘要:BCOR,编码BCL-6共抑制剂(BCOR),与X染色体连锁,是多种血液恶性肿瘤(包括骨髓增生异常综合征)的体细胞突变靶点。Shiro Tara等人既往发现造血室缺失Bcor4号外显子的小鼠(BcorΔE4/y)会进展出NOTCH依赖性的急性T细胞淋巴细胞白血

Cell :复旦教授破译TET2蛋白三维结构,有望用于白血病药物研发

经过逾4年的研究,复旦大学生物医学研究院徐彦辉课题组首次成功解析了哺乳动物骨髓造血关键蛋白TET2的三维结构,这将对血液肿瘤(即血癌、白血病)治疗性药物的开发具有重大意义。上述成果昨日(6日)已在线发表于国际顶级学术期刊《细胞》杂志上,引起世界同行广泛关注。哺乳动物TET蛋白家族有3个成员,即TET1蛋白、TET2蛋白和TET3蛋白。TET蛋白在哺乳动物发育和骨髓造血等关键生命过程中,扮演至关重

Cell:复旦大学研究院解析骨髓造血关键蛋白TET2三维结构

复旦大学生物医学研究院研究员徐彦辉课题组经4年多研究,首次成功解析了哺乳动物骨髓造血关键蛋白TET2的三维结构。该成果对研究多种疾病的发病机制,尤其对血液肿瘤(如髓系白血病)治疗性药物开发有重大意义。相关论文日前在线发表在国际学术期刊《细胞》杂志上。 哺乳动物TET蛋白家族有3个成员,即TET1蛋白、TET2蛋白和TET3蛋白,在哺乳动物发育和骨髓造血等关键生命过程